Analyst consensus rating
Rigel Pharmaceuticals Analyst Rating: none
Direct answer
Rigel Pharmaceuticals's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $63.00.
Forecast evidence checked October 19, 2026.
Get free Rigel Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $45.97
- Average price target
- $63.00
- High price target
- $85.00
- Low price target
- $43.00
- Low target gap
- -6.5%
- Target upside
- +37%
- High target gap
- +84.9%
- Target range width
- 91.4%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rigel Pharmaceuticals?
Rigel Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $63.00.
How far are Rigel Pharmaceuticals's low and high targets from the recorded price?
The low target implies -6.5%, while the high target implies +84.9%.
How many analysts are included in Rigel Pharmaceuticals's consensus?
The verified consensus includes 5 analysts.
How is Rigel Pharmaceuticals's target upside or downside calculated?
The average target of $63.00 is divided by the recorded price of $45.97, then one is subtracted to produce +37%. This does not guarantee a future return.
When was Rigel Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.